Manish R. Patel

16.1k total citations · 4 hit papers
357 papers, 8.0k citations indexed

About

Manish R. Patel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Manish R. Patel has authored 357 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 237 papers in Oncology, 114 papers in Pulmonary and Respiratory Medicine and 95 papers in Molecular Biology. Recurrent topics in Manish R. Patel's work include Cancer Immunotherapy and Biomarkers (81 papers), Chronic Lymphocytic Leukemia Research (51 papers) and Advanced Breast Cancer Therapies (50 papers). Manish R. Patel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (81 papers), Chronic Lymphocytic Leukemia Research (51 papers) and Advanced Breast Cancer Therapies (50 papers). Manish R. Patel collaborates with scholars based in United States, United Kingdom and Germany. Manish R. Patel's co-authors include Jeffrey R. Infante, James L. Gulley, Todd M. Bauer, Ian W. Flinn, Howard A. Burris, Gerald S. Falchook, Karen Kelly, Michael S. Gordon, Ding Wang and Andrea B. Apolo and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Manish R. Patel

344 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Jeffrey R. Infante, Manish R. Patel et al. Journal of Clinical Oncology profile →
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations Manish R. Patel, Jeffrey R. Infante et al. profile →
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

2019 319 citations Kathleen N. Moore, Manish R. Patel et al. profile →
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

2021 192 citations Gerald S. Falchook, Jeffrey R. Infante et al. profile →

Peers

Countries citing papers authored by Manish R. Patel

Since Specialization

Citations

This map shows the geographic impact of Manish R. Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manish R. Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manish R. Patel more than expected).

Fields of papers citing papers by Manish R. Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manish R. Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manish R. Patel. The network helps show where Manish R. Patel may publish in the future.

Co-authorship network of co-authors of Manish R. Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Manish R. Patel. A scholar is included among the top collaborators of Manish R. Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manish R. Patel. Manish R. Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors 2024 ·Clinical Therapeutics ·Gerald S. Falchook, Amita Patnaik, Debra L. Richardson, R. Donald Harvey, Manish Sharma, Navid Hafez, Erika Hamilton, Sarina A. Piha‐Paul, Minal Barve, Trisha M. Wise‐Draper, Manish R. Patel, Afshin Dowlati, (unknown), Shou‐Ching Tang, (unknown), Izabela A. Malinowska, (unknown), Alina Striha, (unknown)	1
2	Abstract CT156: A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies 2024 ·Cancer Research ·Jennifer A. Woyach, Michael Tees, (unknown), (unknown), Su Young Kim, Manish R. Patel	2
3	Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Drew Rasco, Melissa L. Johnson, Manish R. Patel, Angela Alistar, Julia W. Cohen, (unknown), (unknown), Etah S. Kurland	2
4	Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. 2024 ·Journal of Clinical Oncology ·Manish R. Patel, Rachel M. Layman, Michael Danso, David Cosgrove, Marjorie E. Zettler, (unknown), Erika Hamilton	4
5	VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors (1275) 2023 ·Gynecologic Oncology ·Timothy A. Yap, Manish R. Patel, Brian S. Henick, Kathleen N. Moore, Alexandra Léary, (unknown), (unknown), Hui Zhang, Maria Roche, Kate J. Newberry, (unknown), Dejan Juric	1
6	A cross‐sectional study of ageing at the mouse neuromuscular junction and effects of an experimental therapeutic approach for dynapenia 2023 ·The Journal of Physiology ·Yi Li, Manish R. Patel, (unknown), Minghua Wu, S. Gatti, (unknown), Peter Wipf, Yomna Badawi, Stephen D. Meriney	3
7	OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study 2023 ·Journal of Thoracic Oncology ·Melissa L. Johnson, Mark M. Awad, (unknown), Martin Gutierrez, (unknown), Sarina A. Piha‐Paul, Toshihiko Doi, Toru Satoh, Nobuhiko Okamoto, (unknown), (unknown), (unknown), Xiaozhong Qian, (unknown), (unknown), Rastislav Mucha, Hillarie Plessner Windish, Manish R. Patel	23
8	The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study 2023 ·Cancer Discovery ·Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer, (unknown), (unknown), (unknown), (unknown), (unknown), Mrinal M. Gounder	55
9	First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma 2023 ·Molecular Cancer Therapeutics ·Erika Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer, Janet L. Karlix, Jorge Zerón-Medina, (unknown), Paola Marco‐Casanova, Ganesh Moorthy, Maureen M. Hattersley, (unknown), Pat Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore	14
10	2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies 2022 ·International Journal of Gynecological Cancer ·Nicole Concin, Manish R. Patel, Vicky Makker, Ana Oaknin, Sandro Pignata, Floor Backes, Antonio González-Martı́n, Ramez N. Eskander, Bhavana Pothuri, Debra L. Richardson, Angeles Alvarez Secord, Els Van Nieuwenhuysen, Joyce F. Liu, Fernanda Musa, Richard T. Penson, Kenton Wride, Rachel L. Dusek, T. Cameron, Erika Hamilton	0
11	Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study 2022 ·Clinical Cancer Research ·Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana H. Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, (unknown), Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach	21
12	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor 2021 ·Clinical Cancer Research ·David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne F. Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, (unknown), Aimee Bence Lin, Manish R. Patel	37
13	Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours 2020 ·British Journal of Clinical Pharmacology ·Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, (unknown), Floris A. de Jong, Apostolia M. Tsimberidou	49
14	Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia 2019 ·American Journal of Hematology ·Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel	33
15	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im	67
16	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Maura N. Dickler, Cristina Saura, Donald Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bédard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, (unknown), Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga	57
17	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma 2018 ·Clinical Cancer Research ·David S. Hong, Kathleen N. Moore, Manish R. Patel, Stefan C. Grant, Howard A. Burris, William N. William, Suzanne F. Jones, Funda Meric‐Bernstam, Jeffrey R. Infante, (unknown), Wei Zhang, Ricardo Martínez, Sameera R. Wijayawardana, Richard P. Beckmann, Aimee Bence Lin, Cathy Eng, Johanna C. Bendell	62
18	A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer 2017 ·Clinical Cancer Research ·Lee S. Schwartzberg, Denise A. Yardley, Anthony Elias, Manish R. Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy Peterson, Martha Blaney, Joyce Steinberg, Jacqueline A. Gibbons, Tiffany A. Traina	42
19	A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors 2017 ·Clinical Cancer Research ·Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmañà, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Fernández Montés, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, (unknown), Lindsey Rolfe, Ronnie Shapira‐Frommer	186
20	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies 2017 ·Blood ·Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, (unknown), Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz	183

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact